166 related articles for article (PubMed ID: 15456249)
1. Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications.
Tavares FX; Deaton DN; Miller LR; Wright LL
J Med Chem; 2004 Oct; 47(21):5057-68. PubMed ID: 15456249
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
Tavares FX; Deaton DN; Miller AB; Miller LR; Wright LL; Zhou HQ
J Med Chem; 2004 Oct; 47(21):5049-56. PubMed ID: 15456248
[TBL] [Abstract][Full Text] [Related]
3. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
4. Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2004 Oct; 14(19):4897-902. PubMed ID: 15341947
[TBL] [Abstract][Full Text] [Related]
5. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
Barrett DG; Boncek VM; Catalano JG; Deaton DN; Hassell AM; Jurgensen CH; Long ST; McFadyen RB; Miller AB; Miller LR; Payne JA; Ray JA; Samano V; Shewchuk LM; Tavares FX; Wells-Knecht KJ; Willard DH; Wright LL; Zhou HQ
Bioorg Med Chem Lett; 2005 Aug; 15(15):3540-6. PubMed ID: 15982880
[TBL] [Abstract][Full Text] [Related]
6. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Ray JA; Samano V; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2006 Mar; 16(6):1735-9. PubMed ID: 16376075
[TBL] [Abstract][Full Text] [Related]
7. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity.
Setti EL; Davis D; Janc JW; Jeffery DA; Cheung H; Yu W
Bioorg Med Chem Lett; 2005 Mar; 15(5):1529-34. PubMed ID: 15713422
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
[TBL] [Abstract][Full Text] [Related]
9. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
[TBL] [Abstract][Full Text] [Related]
10. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
Crane SN; Black WC; Palmer JT; Davis DE; Setti E; Robichaud J; Paquet J; Oballa RM; Bayly CI; McKay DJ; Somoza JR; Chauret N; Seto C; Scheigetz J; Wesolowski G; Massé F; Desmarais S; Ouellet M
J Med Chem; 2006 Feb; 49(3):1066-79. PubMed ID: 16451072
[TBL] [Abstract][Full Text] [Related]
11. A structural screening approach to ketoamide-based inhibitors of cathepsin K.
Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Wells-Knecht KJ; Wright LL
Bioorg Med Chem Lett; 2005 May; 15(9):2209-13. PubMed ID: 15837295
[TBL] [Abstract][Full Text] [Related]
12. Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity.
Ayesa S; Lindquist C; Agback T; Benkestock K; Classon B; Henderson I; Hewitt E; Jansson K; Kallin A; Sheppard D; Samuelsson B
Bioorg Med Chem; 2009 Feb; 17(3):1307-24. PubMed ID: 19124252
[TBL] [Abstract][Full Text] [Related]
13. Acyclic, orally bioavailable ketone-based cathepsin K inhibitors.
Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Samano V; Tavares FX; Wells-Knecht KJ; Wright LL; Zhou HQ
Bioorg Med Chem Lett; 2007 Jan; 17(1):22-7. PubMed ID: 17157021
[TBL] [Abstract][Full Text] [Related]
14. Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.
Marquis RW; Yamashita DS; Ru Y; LoCastro SM; Oh HJ; Erhard KF; DesJarlais RL; Head MS; Smith WW; Zhao B; Janson CA; Abdel-Meguid SS; Tomaszek TA; Levy MA; Veber DF
J Med Chem; 1998 Sep; 41(19):3563-7. PubMed ID: 9733481
[No Abstract] [Full Text] [Related]
15. Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.
Barrett DG; Catalano JG; Deaton DN; Long ST; Miller LR; Tavares FX; Wells-Knecht KJ; Wright LL; Zhou HQ
Bioorg Med Chem Lett; 2004 May; 14(10):2543-6. PubMed ID: 15109647
[TBL] [Abstract][Full Text] [Related]
16. Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.
Boros EE; Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Paulick MG; Shewchuk LM; Thompson JB; Willard DH; Wright LL
Bioorg Med Chem Lett; 2004 Jul; 14(13):3425-9. PubMed ID: 15177446
[TBL] [Abstract][Full Text] [Related]
17. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.
Black WC; Bayly CI; Davis DE; Desmarais S; Falgueyret JP; Léger S; Li CS; Massé F; McKay DJ; Palmer JT; Percival MD; Robichaud J; Tsou N; Zamboni R
Bioorg Med Chem Lett; 2005 Nov; 15(21):4741-4. PubMed ID: 16154747
[TBL] [Abstract][Full Text] [Related]
18. Beta-substituted cyclohexanecarboxamide cathepsin K inhibitors: modification of the 1,2-disubstituted aromatic core.
Robichaud J; Bayly CI; Black WC; Desmarais S; Léger S; Massé F; McKay DJ; Oballa RM; Pâquet J; Percival MD; Truchon JF; Wesolowski G; Crane SN
Bioorg Med Chem Lett; 2007 Jun; 17(11):3146-51. PubMed ID: 17408953
[TBL] [Abstract][Full Text] [Related]
19. Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors.
Yamashita DS; Xie R; Lin H; Wang B; Shi SD; Quinn CJ; Hemling ME; Hissong C; Tomaszek TA; Veber DF
J Pept Res; 2004 Mar; 63(3):265-9. PubMed ID: 15049838
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
Stoch SA; Wagner JA
Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
